nirmatrelvir

component of COVID-19 drug Paxlovid

Also Known As:

(1R,2S,5S)-N-((1S)-1-cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-6,6-dimethyl-3-(3-methyl-N-(trifluoroacetyl)-l-valyl)-3-azabicyclo(3.1.0)hexane-2-carboxamide; PF-07321332; PF07321332

Networked: 200 relevant articles (24 outcomes, 29 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Binks, Michael: 2 articles (10/2022 - 01/2022)
2.	Damle, Bharat: 2 articles (10/2022 - 01/2022)
3.	Shi, Haihong: 2 articles (10/2022 - 01/2022)
4.	Toussi, Sima S: 2 articles (10/2022 - 01/2022)
5.	Adachi, Eisuke: 2 articles (02/2022 - 01/2022)
6.	Chong, Zhenlu: 2 articles (02/2022 - 01/2022)
7.	Duong, Calvin: 2 articles (02/2022 - 01/2022)
8.	Fujisaki, Seiichiro: 2 articles (02/2022 - 01/2022)
9.	Furusawa, Yuri: 2 articles (02/2022 - 01/2022)
10.	Godbole, Sucheta: 2 articles (02/2022 - 01/2022)

Related Diseases

1.	COVID-19 01/01/2022 - "Our in vitro data suggest that the efficacy of the specific Mpro inhibitor nirmatrelvir is not compromised in current COVID-19 variants." 11/01/2023 - "Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records." 03/17/2023 - "Green adherent degradation kinetics study of Nirmatrelvir, an oral anti-COVID-19: characterization of degradation products using LC-MS with insilico toxicity profile." 03/01/2023 - "The present in silico risk assessment study is focused on the aquatic toxicity prediction of 81 pharmaceuticals where 77 are most-used pharmaceuticals for COVID-19 throughout the world based on the literature along with one drug nirmatrelvir [PF-07321332] approved for emergency use by US-FDA and three other molecules under clinical trial. " 01/01/2023 - "Our study revealed a significant positive correlation between a decrease in CD8+ T cell counts and progression and mortality of hospitalized COVID-19 patients treated with Nirmatrelvir. "
2.	Infections 10/01/2023 - "In this study, population pharmacokinetic modeling with clinical study data was employed to explore the pharmacokinetic profile of nirmatrelvir in older adult Chinese patients with COVID-19 infection. " 10/01/2023 - "Nirmatrelvir is prescribed extensively in older adult patients to treat the coronavirus disease 2019 (COVID-19) infection. " 10/01/2023 - "Population pharmacokinetic modeling and simulation for nirmatrelvir exposure assessment in Chinese older patients with COVID-19 infection." 01/01/2023 - "Both mutant viruses showed attenuated phenotypes in a male hamster infection model, maintained airborne transmissibility, and were outcompeted by wild-type virus in co-infection experiments in the absence of nirmatrelvir, but less so in the presence of the drug. " 01/01/2023 - "This cohort study found that in people with SARS-CoV-2 infection who had at least 1 risk factor for progression to severe disease, treatment with nirmatrelvir within 5 days of a positive SARS-CoV-2 test result was associated with reduced risk of PCC across the risk spectrum in this cohort and regardless of vaccination status and history of prior infection; the totality of findings suggests that treatment with nirmatrelvir during the acute phase of COVID-19 may reduce the risk of post-acute adverse health outcomes."
3.	Disease Progression 01/01/2023 - "Notably, use of MK-4482 and PF-07321332 in combination improved the individual inhibitory effect of both drugs, resulting in milder disease progression, stronger reduction of virus shedding from mucosal tissues of the upper respiratory tract, stronger reduction of viral replication in the lower respiratory tract, and reduced lung pathology. " 10/08/2022 - "Nirmatrelvir plus ritonavir use was associated with lower risks of death (0·34 [0·22-0·52]), hospitalisation (0·76 [0·67-0·86]), and in-hospital disease progression (0·57 [0·38-0·87]) than non-use was. " 08/01/2023 - "Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study." 01/01/2022 - "For non-hospitalized patients with COVID-19 who are at risk of disease progression, the currently recommended three anti-viral agents, nirmatrelvir plus ritonavir, molnupiravir and remdesivir, should continue to be recommended for the prevention of disease progression. " 11/17/2022 - "A protease inhibitor called nirmatrelvir coupled with ritonavir (NMV/r), which acts as a CYP3A inhibitor, delivered as an oral formulation, has shown much promise in preventing disease progression in high-risk patients with no need for supplemental oxygen administration. "
4.	Severe Acute Respiratory Syndrome 01/01/2023 - "This study aims to investigate the activity of the remdesivir-nirmatrelvir combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and to report a case of Coronavirus Disease 2019 (COVID-19) cured with this combination. " 01/01/2023 - "Oral nirmatrelvir plus ritonavir (Paxlovid™) is an effective treatment option for coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). " 01/01/2023 - "Nirmatrelvir (PF-07321332) is a nitrile-bearing small-molecule inhibitor that, in combination with ritonavir, is used to treat infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). "
5.	Post-Acute COVID-19 Syndrome 01/01/2022 - "Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies." 12/27/2022 - "VA Finds Nirmatrelvir Associated With Lower Risk of Long COVID." 01/01/2022 - "In the final case, an individual with presumed Long COVID for 2 years reported substantial improvement in chronic symptoms when taking nirmatrelvir following SARS-CoV-2 re-infection. "

Related Drugs and Biologics

1.	Ritonavir (Norvir)
2.	molnupiravir
3.	Antiviral Agents (Antivirals)
4.	nirmatrelvir and ritonavir drug combination
5.	remdesivir
6.	Monoclonal Antibodies
7.	plitidepsin (aplidine)
8.	lufotrelvir
9.	AT-511
10.	Protease Inhibitors (Protease Inhibitor)

Related Therapies and Procedures

1.	Therapeutics
2.	Renal Dialysis (Hemodialysis)
3.	Contraindications
4.	Drug Therapy (Chemotherapy)
5.	Oral Administration